Morgan Stanley on Cipla | Morgan Stanley maintains an 'overweight' call on the shares of Cipla with a target price of Rs 1,122. The brokerage house says that there is a good visibility of 2-3 complex launches per year for next three years.

Nomura on Cipla | Nomura maintains a 'buy' call on the shares of Cipla with a target price of Rs 1,195. The company maintained a margin guidance of 21-22 percent for FY23.

HSBC on Cipla | HSBC maintains a 'buy' call on the shares of Cipla with a target price of Rs 1,180. US approval and launch of Abraxane, Revlimid, Advair generics, key catalysts, says the brokerage house.

Credit Suisse on Cipla | Credit Suisse maintains an 'outperform' rating on the shares of Cipla with a target price of Rs 1,100. The positive stance is driven by strong pipeline in respiratory and injectable space in US.